553 related articles for article (PubMed ID: 16022804)
1. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.
Garside R; Stein K; Castelnuovo E; Pitt M; Ashcroft D; Dimmock P; Payne L
Health Technol Assess; 2005 Jul; 9(29):iii, xi-xiii,1-230. PubMed ID: 16022804
[TBL] [Abstract][Full Text] [Related]
2. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.
Pitt M; Garside R; Stein K
Br J Dermatol; 2006 Jun; 154(6):1137-46. PubMed ID: 16704646
[TBL] [Abstract][Full Text] [Related]
3. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.
Green C; Colquitt JL; Kirby J; Davidson P; Payne E
Health Technol Assess; 2004 Nov; 8(47):iii,iv, 1-120. PubMed ID: 15527669
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC
BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121
[TBL] [Abstract][Full Text] [Related]
7. How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema?
Wilkes SR; Nankervis H; Tavernier E; Maruani A; Williams HC
J Invest Dermatol; 2016 Oct; 136(10):1944-1949. PubMed ID: 27265005
[TBL] [Abstract][Full Text] [Related]
8. Topical pimecrolimus for eczema.
Ashcroft DM; Chen LC; Garside R; Stein K; Williams HC
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005500. PubMed ID: 17943859
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
Yang LP; Curran MP
Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720
[TBL] [Abstract][Full Text] [Related]
10. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
11. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
Wellington K; Jarvis B
Drugs; 2002; 62(5):817-40. PubMed ID: 11929333
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age.
Ellis CN; Kahler KH; Grueger J; Chang J
Am J Clin Dermatol; 2006; 7(2):133-9. PubMed ID: 16605293
[TBL] [Abstract][Full Text] [Related]
14. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.
Delea TE; Gokhale M; Makin C; Hussein MA; Vanderpoel J; Sandman T; Chang J; Sung J; Pinkston P; Gause D; Jackson M
J Manag Care Pharm; 2007 May; 13(4):349-59. PubMed ID: 17506601
[TBL] [Abstract][Full Text] [Related]
15. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
16. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
de Bruin-Weller MS; Bruijnzeel-Koomen CA
Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Breuer K; Werfel T; Kapp A
Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids.
Poole CD; Chambers C; Allsopp R; Currie CJ
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):674-8. PubMed ID: 20565562
[TBL] [Abstract][Full Text] [Related]
19. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
20. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.
El-Batawy MM; Bosseila MA; Mashaly HM; Hafez VS
J Dermatol Sci; 2009 May; 54(2):76-87. PubMed ID: 19303745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]